A Phase 1/2 interventional study of Fitusiran (SAR439774) in Hemophilia A and Hemophilia B, sponsored by Genzyme, a Sanofi Company. Completed at 12 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-05.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.
Among the 10 studies testing fitusiran in Hemophilia A, this one is the 8th largest by enrollment, is the only one that started in 2015, is the only one in phase 1/2, and was the 2nd registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Belgium, Brazil and 9 more countries
Ages 1–11 · Men only
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
By country, each count listing its studies:
fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 7 · Phase 4 1
First in 2014; this study’s year is marked. 1 started in 2015.
This study's enrollment of 34 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 70 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
29 studies in Hemophilia A by Sanofi: 4 open now, 8 under way, 3 of them phase 3. Of 21 finished, 14 (67%) have results posted.
Among the 29 studies in Hemophilia A by Sanofi, this one is the 16th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2015, is one of 2 in phase 1/2, and was the 10th registered.
Sanofi’s Hemophilia A studies by the year they started, since 2009.
1 of the studies testing fitusiran in Hemophilia A that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05662319Phase 3SanofiA Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | 2027-03-25 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing fitusiran in Hemophilia A, from their registry updates:
Among Sanofi’s 29 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the long-term safety and tolerability of fitusiran in male patients with moderate or severe hemophilia A or B
Secondary Objectives:
It is anticipated that patients in this study will receive treatment with open label fitusiran for approximately 7 years or until fitusiran becomes commercially available, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be administered subcutaneous (SC) fitusiran once monthly or every 2 months according to the dose selection rules defined in protocol.
Drug: Fitusiran (SAR439774)
Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An SAE is any untoward medical occurrence that results: death or life-threatening or inpatient hospitalization or prolongation of existing hospitalization or persistent or significant disability or congenital anomaly or medically important event. All AEs collected in LTE14762 were considered TEAE because all participants received dose in the parent study. AEs of special interest (AESI) are alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>3× upper limit of normal (ULN) or suspected or confirmed thromboembolic events or severe or serious injection site reactions or systemic injection associated reactions or cholecystitis or cholelithiasis.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology
Blood samples were collected to determine the hematology laboratory significant abnormalities. Here, DFB = decrease from baseline, NB = non-black, and B = black.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Number of Participants With Potentially Clinically Significant Abnormality: Clinical Chemistry
Blood samples were collected to determine the clinical chemistry laboratory abnormalities. Here, mmol/L = millimoles per liter, LLN = lower limit of normal, mg/L = milligram per liter, umol/L = micromoles per liter, mL/min = milliliter per minute, m\^2 = meter square, CB = conjugated bilirubin, and DB = direct bilirubin.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis
Urine samples collected to determine the significant abnormalities in urine.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs
Participants vital signs were examined to determine the abnormalities. Vital signs included weight, supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP). Here, mmHg = millimeter of mercury, and IFB = increase from baseline.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Number of Participants With Potentially Clinically Significant Abnormality: Electrocardiogram (ECG)
Standard 12-lead ECGs were recorded after at least 15 minutes in the supine position using an electrocardiographic device. The following were assessed: heart rate, rhythm, interval between the peaks of successive QRS complexes (RR), interval from the beginning of the P wave until the beginning of the QRS complex (PR), interval from start of the Q wave to the end of the S wave (QRS), interval between the start of the Q wave and the end of the T wave (QT), QT interval corrected for heart rate (QTc) automatic correction evaluation, QRS axis, left ventricular hypertrophy criteria, right ventricular hypertrophy criteria, repolarization charges, and overall cardiac impression for each participant. Here, msec = milliseconds.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Number of Participants With Potentially Clinically Significant Abnormality: Physical Examination
Physical examination included, at a minimum, an assessment of the participant's general appearance; skin; head, eyes, ears, nose, and throat; examinations of lymph nodes, abdomen, extremities/joints, neurological and mental status; heart and respiratory auscultation; peripheral arterial pulse; and pupil, knee, achilles, and plantar reflexes.
Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Annualized Bleeding Rate (ABR) During the Efficacy Period
The ABR was annualized for each participant using the following formula: ABR = total number of bleeding events/total number of days in the respective period x 365.25. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Annualized Spontaneous Bleeding Rate During the Efficacy Period
A spontaneous bleeding episode was defined as a bleeding event that occurred for no apparent or known reason, particularly into the joints, muscles, and soft tissues. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Annualized Joint Bleeding Rate During the Efficacy Period
A joint bleeding episode was defined as an event that is characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin over the joint; 2) increasing pain; or 3) progressive loss of range of motion or difficulty in using the limb as compared with baseline. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Time Intervals Between Bleeding Events
Bleed-free duration was defined as the time interval between 2 protocol-defined treated bleeding events, excluding events that occurred during the intercurrent periods.
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Annualized Weight-Adjusted Consumption of Coagulation Factor VIII (FVIII) and Coagulation Factor IX (FIX)
Number of coagulation factor injections per bleed was determined. IU= international units, and kg= kilogram.
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Recombinant Factor VIIa (rFVIIa)
Number of BPA injections per bleed was determined.
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Activated Prothrombin Complex Concentrate (aPCC)
Number of BPA injections per bleed was determined.
Time frame: From Day 29 up to end of the study, maximum of up to 76 months
Change From Baseline in EuroQoL 5-Dimension 5-level Questionnaire (EQ-5D-5L) Index and Visual Analog Scale (VAS) Scores at Month 24
The EQ-5D-5L is a standardized and disease-generic instrument for use as a measure of quality of life (QoL) outcome. The EQ-5D-5L consists of 2 parts: EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system included questions for each of following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS recorded participant's self-rated health on a vertical 20-centimeter. VAS scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The EQ-5D-5L questionnaire scores range from 0-100, where 0= worst self-perceived health and 100= best self-perceived health. Positive change from baseline indicates an improvement in QoL. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.
Time frame: Baseline and Month 24
Change From Baseline in Hemophilia Quality of Life Questionnaire (Haem-A-QoL) Total Score and Physical Health Scores at Month 24
The Haem-A-QoL questionnaire is psychometrically tested QoL assessment instrument for participants with hemophilia and includes 46 items contributing to 10 QoL domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Scoring for each item is based on a 5-point Likert scale (1= never, 2= rarely, 3= sometimes, 4= often, and 5= all the time), and the physical health and total transformed scores range from 0 to 100. Higher scores indicated greater impairment. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.
Time frame: Baseline and Month 24
Antithrombin Activity Level at the End of Treatment Regimen
The AT activity level was analyzed up to end of treatment regimen. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Thrombin Generation at the End of Treatment Regimen
The TG data was analyzed by CoagScope and assay performed using calibrated automated thrombogram method. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.
Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Maximum Observed Concentration (Cmax) of Fitusiran
Cmax was defined as maximum plasma concentration observed. The non-compartmental Pharmacokinetic (PK) analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24
Time to Reach the Maximum Concentration (Tmax) of Fitusiran
tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24
Area Under the Concentration Versus Time Curve From Time 0 to the Real Time (AUClast) of Fitusiran
AUClast was defined as area under the concentration versus time curve from time 0 to the last measurable concentration. The non-compartmental PK analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24
Area Under the Concentration Versus Time Curve Extrapolated to Infinity (AUCinf) of Fitusiran
AUCinf was defined as area under the concentration versus time curve extrapolated to infinity. The non-compartmental PK analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Terminal Half-Life (t1/2z) of Fitusiran
t1/2z associated with the terminal slope (λz) determined according to the following equation: t1/2z = 0.693/λz; where, λz is the slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale. The non-compartmental PK analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Apparent Total Body Clearance (CL/F) of Fitusiran
CL/F was defined as apparent clearance of study drug from the body. The non-compartmental PK analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Apparent Volume of Distribution at the Steady State After Single Extravascular Dose (Vss/F) of Fitusiran
Vss/F was defined as apparent volume of distribution of study drug at steady state concentration. The non-compartmental PK analysis was performed.
Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Recovery of Fraction of the Dose Excreted in Urine (fe) in 0-24 Hours After Fitusiran Administration
fe was defined as the amount of fitusiran excreted in urine in 0-24 hour. The non-compartmental PK analysis was performed.
Time frame: Postdose, 0 to 6 hours, 6 to 12 hours, 12 to 24 hours at Month 24
The study was conducted at 13 centers in 5 countries between 18 September 2015 and 21 March 2023. A total of 34 participants were enrolled in this study.
| Milestone | Original Dose Regimen [Safety Analysis Set 1 (SAS 1)] | Antithrombin (AT)-Based Dose Regimen [Safety Analysis Set 2 (SAS 2)] |
|---|---|---|
| Started | 34 | 0 |
| Completed | 18 | 0 |
| Not completed | 16 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other | 4 | 0 |
| Milestone | Original Dose Regimen [Safety Analysis Set 1 (SAS 1)] | Antithrombin (AT)-Based Dose Regimen [Safety Analysis Set 2 (SAS 2)] |
|---|---|---|
| Started | 0 | 18 |
| Completed | 0 | 12 |
| Not completed | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: More than 1 at measurement <15% | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Other | 0 | 3 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An SAE is any untoward medical occurrence that results: death or life-threatening or inpatient hospitalization or prolongation of existing hospitalization or persistent or significant disability or congenital anomaly or medically important event. All AEs collected in LTE14762 were considered TEAE because all participants received dose in the parent study. AEs of special interest (AESI) are alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>3× upper limit of normal (ULN) or suspected or confirmed thromboembolic events or severe or serious injection site reactions or systemic injection associated reactions or cholecystitis or cholelithiasis.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Any TEAE | 33 | 14 |
| Any Treatment-emergent SAE | 13 | 1 |
| Any Treatment-emergent AESI | 11 | 1 |
| Any TEAE leading to study drug discontinuation | 5 | 1 |
| Any TEAE leading to death | 1 | 0 |
Blood samples were collected to determine the hematology laboratory significant abnormalities. Here, DFB = decrease from baseline, NB = non-black, and B = black.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Hemoglobin: <= 115 gram per liter (g/L) | 5 | 2 |
| Hemoglobin: >= 185 g/L | 3 | 1 |
| Hemoglobin: DFB >= 20 g/L | 10 | 3 |
| Hematocrit: <= 0.37 fraction of 1 | 8 | 3 |
| Hematocrit: >= 0.55 fraction of 1 | 5 | 2 |
| Erythrocyte Count: >= 6 x 10^12/L | 9 | 3 |
| Platelet Count: < 100 x 10^9/L | 2 | 0 |
| Leukocyte Count: <3 x 10^9/L (NB); <2 x 10^9/L (B) | 3 | 1 |
| Leukocyte Count: >= 16 x 10^9/L | 1 | 1 |
| Neutrophils: <1.5 x 10^9/L (NB); <1 x 10^9/L (B) | 8 | 2 |
| Lymphocytes: > 4 x 10^9/L | 0 | 1 |
| Monocytes: > 0.7 x 10^9/L | 15 | 3 |
| Basophils: > 0.1 x 10^9/L | 4 | 0 |
| Eosinophils:>0.5x10^9/L or >ULN (ULN >=0.5x10^9/L) | 11 | 1 |
Blood samples were collected to determine the clinical chemistry laboratory abnormalities. Here, mmol/L = millimoles per liter, LLN = lower limit of normal, mg/L = milligram per liter, umol/L = micromoles per liter, mL/min = milliliter per minute, m\^2 = meter square, CB = conjugated bilirubin, and DB = direct bilirubin.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Glucose: <= 3.9 mmol/L and < LLN | 13 | 2 |
| Glucose:>=11.1 mmol/L(unfasted);>=7 mmol/L(fasted) | 10 | 2 |
| C-Reactive Protein: > 2 ULN or > 10 mg/L | 20 | 7 |
| Sodium: <= 129 mmol/L | 1 | 0 |
| Potassium: < 3 mmol/L | 2 | 0 |
| Potassium: >= 5.5 mmol/L | 5 | 0 |
| Creatinine: >= 150 umol/L | 1 | 1 |
| Creatinine: >= 30% change from baseline | 13 | 7 |
| Creatinine: >= 100% change from baseline | 2 | 1 |
| Creatinine Clearance: >= 60 - < 90 mL/min/1.73m^2 | 18 | 2 |
| Creatinine Clearance: >= 15 - < 30 mL/min/1.73m^2 | 1 | 1 |
| Uric Acid: < 120 umol/L | 2 | 0 |
| Uric Acid: > 408 umol/L | 20 | 8 |
| ALT: > 1 ULN | 30 | 6 |
| ALT: > 3 ULN | 14 | 1 |
| ALT: > 5 ULN | 6 | 1 |
| ALT: > 10 ULN | 2 | 0 |
| ALT: > 20 ULN | 1 | 0 |
| AST: > 1 ULN | 22 | 7 |
| AST: > 3 ULN | 8 | 1 |
| AST: > 5 ULN | 5 | 0 |
| AST: > 10 ULN | 1 | 0 |
| Alkaline Phosphatase: > 1.5 ULN | 4 | 0 |
| Total Bilirubin: > 1.5 ULN | 4 | 2 |
| CB: DB >35% Bilirubin and Bilirubin >1.5 ULN | 3 | 1 |
Urine samples collected to determine the significant abnormalities in urine.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis | 0 | 0 |
Participants vital signs were examined to determine the abnormalities. Vital signs included weight, supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP). Here, mmHg = millimeter of mercury, and IFB = increase from baseline.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| SSBP: >= 160 mmHg; IFB >= 20 mmHg | 1 | 0 |
| SDBP: <= 45 mmHg; DFB >= 20 mmHg | 1 | 0 |
| Weight: >= 5% DFB | 8 | 3 |
| Weight: >= 5% IFB | 15 | 9 |
Standard 12-lead ECGs were recorded after at least 15 minutes in the supine position using an electrocardiographic device. The following were assessed: heart rate, rhythm, interval between the peaks of successive QRS complexes (RR), interval from the beginning of the P wave until the beginning of the QRS complex (PR), interval from start of the Q wave to the end of the S wave (QRS), interval between the start of the Q wave and the end of the T wave (QT), QT interval corrected for heart rate (QTc) automatic correction evaluation, QRS axis, left ventricular hypertrophy criteria, right ventricular hypertrophy criteria, repolarization charges, and overall cardiac impression for each participant. Here, msec = milliseconds.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Ventricular Rate: < 50 beats/min | 1 | 0 |
| Ventricular Rate: > 90 beats/min | 8 | 5 |
| Ventricular Rate: >90 beats/min;IFB >=20 beats/min | 3 | 1 |
| Ventricular Rate: > 100 beats/min | 5 | 1 |
| Ventricular Rate:>100 beats/min;IFB >=20 beats/min | 1 | 0 |
| PR Interval: > 200 msec | 3 | 0 |
| PR Interval: > 200 msec; IFB >= 25% | 2 | 0 |
| PR Interval: > 220 msec | 2 | 0 |
| PR Interval: > 220 msec; IFB >= 25% | 2 | 0 |
| PR Interval: > 240 msec | 2 | 0 |
| PR Interval: > 240 msec;IFB >= 25% | 2 | 0 |
| QRS Interval: > 110 msec | 8 | 3 |
| QRS Interval: > 110 msec; IFB >= 25% | 3 | 0 |
| QRS Interval: > 120 msec | 3 | 2 |
| QRS Interval: > 120 msec; IFB >= 25% | 3 | 0 |
| QTc Bazett: > 450 msec | 2 | 4 |
| QTc Bazett: > 480 msec | 1 | 1 |
| QTc Bazett: IFB (30-60) msec | 8 | 4 |
| QTc Fridericia: > 450 msec | 1 | 1 |
| QTc Fridericia: > 480 msec | 0 | 1 |
| QTc Fridericia: IFB (30-60) msec | 4 | 4 |
Physical examination included, at a minimum, an assessment of the participant's general appearance; skin; head, eyes, ears, nose, and throat; examinations of lymph nodes, abdomen, extremities/joints, neurological and mental status; heart and respiratory auscultation; peripheral arterial pulse; and pupil, knee, achilles, and plantar reflexes.
| Participants | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Number of Participants With Potentially Clinically Significant Abnormality: Physical Examination | 17 | 2 |
The ABR was annualized for each participant using the following formula: ABR = total number of bleeding events/total number of days in the respective period x 365.25. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).
| bleeding events per year | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Annualized Bleeding Rate (ABR) During the Efficacy Period | 3.035 (1.845 to 4.992) | 3.929 (1.622 to 9.520) |
A spontaneous bleeding episode was defined as a bleeding event that occurred for no apparent or known reason, particularly into the joints, muscles, and soft tissues. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).
| bleeding events per year | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Annualized Spontaneous Bleeding Rate During the Efficacy Period | 2.60 ± 5.96 | 3.96 ± 11.64 |
A joint bleeding episode was defined as an event that is characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin over the joint; 2) increasing pain; or 3) progressive loss of range of motion or difficulty in using the limb as compared with baseline. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).
| bleeding events per year | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Annualized Joint Bleeding Rate During the Efficacy Period | 3.51 ± 6.97 | 4.78 ± 11.76 |
Bleed-free duration was defined as the time interval between 2 protocol-defined treated bleeding events, excluding events that occurred during the intercurrent periods.
| days | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Time Intervals Between Bleeding Events | 368.50 (56.0 to 1576.0) | 249.00 (11.0 to 427.0) |
Number of coagulation factor injections per bleed was determined. IU= international units, and kg= kilogram.
| IU/kg per year | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| FVIII | 63.66 ± 81.29 | 52.13 ± 8.50 |
| FIXs | 110.26 ± 93.74 | 108.63 ± 138.42 |
Number of BPA injections per bleed was determined.
| microgram/kg per year | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Recombinant Factor VIIa (rFVIIa) | 1316.19 ± 2631.87 | 1431.84 ± 2369.29 |
Number of BPA injections per bleed was determined.
| units/kg per year | Original Dose Regimen (SAS 1) |
|---|---|
| Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Activated Prothrombin Complex Concentrate (aPCC) | 381.81 ± 409.82 |
The EQ-5D-5L is a standardized and disease-generic instrument for use as a measure of quality of life (QoL) outcome. The EQ-5D-5L consists of 2 parts: EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system included questions for each of following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS recorded participant's self-rated health on a vertical 20-centimeter. VAS scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The EQ-5D-5L questionnaire scores range from 0-100, where 0= worst self-perceived health and 100= best self-perceived health. Positive change from baseline indicates an improvement in QoL. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.
| units on a scale | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Index score | 0.01 ± 0.14 | 0.09 ± 0.06 |
| VAS score | 4.73 ± 18.37 | 16.67 ± 7.64 |
The Haem-A-QoL questionnaire is psychometrically tested QoL assessment instrument for participants with hemophilia and includes 46 items contributing to 10 QoL domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Scoring for each item is based on a 5-point Likert scale (1= never, 2= rarely, 3= sometimes, 4= often, and 5= all the time), and the physical health and total transformed scores range from 0 to 100. Higher scores indicated greater impairment. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.
| units on a scale | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Total score | -0.20 ± 0.47 | 0.02 ± 0.34 |
| Physical health score | -0.14 ± 0.58 | -0.53 ± 0.61 |
The AT activity level was analyzed up to end of treatment regimen. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.
| percentage | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Antithrombin Activity Level at the End of Treatment Regimen | 16.28 ± 4.53 | 24.76 ± 7.36 |
The TG data was analyzed by CoagScope and assay performed using calibrated automated thrombogram method. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.
| nanomoles/liter | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Thrombin Generation at the End of Treatment Regimen | 71.39 ± 24.67 | 32.31 ± 20.05 |
Cmax was defined as maximum plasma concentration observed. The non-compartmental Pharmacokinetic (PK) analysis was performed.
| nanogram per milliliter (ng/mL) | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 86.8 ± 44.1 | 168 ± 74.6 |
| Month 12 | 75.2 ± 50.3 | 149 ± 53.2 |
| Month 24 | 62.5 ± 35.3 | 155 ± 87.9 |
tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.
| hour | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 3.97 (0.50 to 8.08) | 4.00 (2.00 to 8.07) |
| Month 12 | 4.02 (2.00 to 8.00) | 6.00 (2.02 to 8.03) |
| Month 24 | 4.00 (4.00 to 4.00) | 7.83 (4.05 to 8.00) |
AUClast was defined as area under the concentration versus time curve from time 0 to the last measurable concentration. The non-compartmental PK analysis was performed.
| ng*hour/mL | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 1110 ± 486 | 2130 ± 769 |
| Month 12 | 961 ± 551 | 2020 ± 708 |
| Month 24 | 935 ± 550 | 2070 ± 917 |
AUCinf was defined as area under the concentration versus time curve extrapolated to infinity. The non-compartmental PK analysis was performed.
| ng*h/mL | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 1470 ± 441 | 2230 ± 641 |
| Month 12 | 356 ± NA | 2860 ± NA |
t1/2z associated with the terminal slope (λz) determined according to the following equation: t1/2z = 0.693/λz; where, λz is the slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale. The non-compartmental PK analysis was performed.
| hour | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 5.19 ± 1.61 | 5.90 ± 3.83 |
| Month 12 | 3.91 ± NA | 4.94 ± NA |
CL/F was defined as apparent clearance of study drug from the body. The non-compartmental PK analysis was performed.
| liter per hour | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 37.6 ± 13.6 | 38.8 ± 12.7 |
| Month 12 | 143 ± NA | 28.3 ± NA |
Vss/F was defined as apparent volume of distribution of study drug at steady state concentration. The non-compartmental PK analysis was performed.
| liter | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Day 1 | 283 ± 155 | 390 ± 348 |
| Month 12 | 834 ± NA | 204 ± NA |
fe was defined as the amount of fitusiran excreted in urine in 0-24 hour. The non-compartmental PK analysis was performed.
| percentage of study drug | Fitusiran 50 mg | Fitusiran 80 mg |
|---|---|---|
| Recovery of Fraction of the Dose Excreted in Urine (fe) in 0-24 Hours After Fitusiran Administration | 10.7 ± 4.08 | 12.6 ± 4.92 |
Collected over TEAEs data was collected from first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Original Dose Regimen (SAS 1) | 1/34 (2.9%) | 13/34 (38.2%) | 33/34 (97.1%) |
| AT-Based Dose Regimen (SAS 2) | 0/18 (0%) | 1/18 (5.6%) | 13/18 (72.2%) |
| Event | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| CholecystitisHepatobiliary disorders | 2/34 | 0/18 |
| Hepatocellular CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 1/18 |
| Atrial ThrombosisCardiac disorders | 1/34 | 0/18 |
| Gastric Ulcer HaemorrhageGastrointestinal disorders | 1/34 | 0/18 |
| GastritisGastrointestinal disorders | 1/34 | 0/18 |
| Gastroduodenal UlcerGastrointestinal disorders | 1/34 | 0/18 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 1/34 | 0/18 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 1/34 | 0/18 |
| Haemorrhagic Erosive GastritisGastrointestinal disorders | 1/34 | 0/18 |
| Peptic Ulcer HaemorrhageGastrointestinal disorders | 1/34 | 0/18 |
| Event | Original Dose Regimen (SAS 1) | AT-Based Dose Regimen (SAS 2) |
|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 10/34 | 0/18 |
| HeadacheNervous system disorders | 9/34 | 1/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/34 | 1/18 |
| Injection Site ErythemaGeneral disorders | 7/34 | 0/18 |
| NasopharyngitisInfections and infestations | 7/34 | 1/18 |
| DiarrhoeaGastrointestinal disorders | 6/34 | 0/18 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/34 | 1/18 |
| Back PainMusculoskeletal and connective tissue disorders | 6/34 | 0/18 |
| Transaminases IncreasedInvestigations | 5/34 | 1/18 |
| Abdominal PainGastrointestinal disorders | 4/34 | 0/18 |
Safety analysis set 1 included all participants who received at least a partial dose of study drug during the LTE14762 study under the original dose and regimen.
| Age, Continuous(years) | Original Dose Regimen (SAS 1) |
|---|---|
| Mean | 36.6 ± 10.7 |
| Sex: Female, Male(Participants) | Original Dose Regimen (SAS 1) |
|---|---|
| Female | 0 |
| Male | 34 |
| Race/Ethnicity, Customized(Participants) | Original Dose Regimen (SAS 1) |
|---|---|
| Caucasian/White | 33 |
| Asian/Oriental | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2015 to primary completion in Mar 2023, 90 months.
Results were first posted in Jun 2024, 1 year 2 months after primary completion.
Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 90 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fitusiran